TB Alliance: New Report: LIFT-TB Helped Cut Time to Global Uptake of Improved Drug-Resistant TB Treatments from Nearly a Decade to Three Years

13 April 2026

TB Alliance press release

A new independent assessment finds that LIFT-TB (Leveraging Innovation for Faster Treatment of Tuberculosis), an initiative led by TB Alliance in partnership with International Tuberculosis Research Center, South Korea and co-funding by KOICA, played a crucial role in accelerating the global uptake of shorter, more effective treatments for drug-resistant TB. This progress contributed to a broader shift in how new TB treatments are introduced, helping reduce the time from approval to widespread access from the typical 7-9 years to approximately three years.

Launched in 2020, LIFT-TB supported the introduction and scale-up of six-month, all-oral BPaL-based regimens across seven high-burden countries – Indonesia, Kyrgyzstan, Myanmar, the Philippines, Ukraine, Uzbekistan, and Vietnam. The independent assessment by the health consulting firm, IQVIA, found that LIFT-TB was highly successful in meeting its objectives, combining operational research, technical assistance, and system strengthening to rapidly translate innovation into programmatic implementation.

Read the full press release here.

Source: TB Alliance